CLL Global Research Foundation is accepting LOI applications from January 1 through January 23, 2026. The next application period will open in July/August 2026.

Research Priorities

CLL Global Research Foundation will accept Letters of Intent (LOIs) from January 1 through January 23, 2026. The next application period is expected to open in July/August 2026.

1. BTK and BCL-2 Inhibitor Refractory Disease Investigate mechanisms of resistance and develop novel strategies to treat BTK and/or BCL-2 inhibitor–refractory CLL, including rational combinations and sequencing approaches.


2. Immune Dysfunction and Restoration Examine the causes of immune dysregulation in CLL and develop approaches to restore immune function, reduce infection risk, and improve response to vaccines and immunotherapies.


3. Novel Therapeutic Targets and Approaches Identify and validate new molecular targets and innovative therapeutic strategies for CLL, including agents with new mechanisms of action and biomarker-driven approaches to patient selection.


4. High-Risk and Genomically Complex Disease Develop and translate strategies that address early relapse and poor durability in TP53-Disrupted and genomically complex CLL, including TP53-independent therapies and rational combinations.